FIELD: pharmacology.
SUBSTANCE: invention relates to the crystalline free base of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, which is a polymorphic form A with a specific surface area less than or equal to 2 m2/g and a powder X-ray diffraction pattern containing peaks with diffraction angles (2θ) 8.0±0.2, 10.1±0.2 and 11.5±0.2, as well as to pharmaceutical compositions based thereon.
EFFECT: free base with larger particle size and improved physicochemical properties is obtained, which can be used for treatment of cell-proliferative diseases such as cancer.
13 cl, 9 dwg, 13 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ISETHIONATE SALT OF CDK4 SELECTIVE INHIBITOR | 2004 |
|
RU2317296C2 |
| NOVEL CRYSTALLINE FORMS OF SODIUM SALT OF (4-{4-[5-(6-TRIFLUOROMETHYL-PYRIDIN-3-YLAMINO)PYRIDIN-2-YL]PHENYL}CYCLOHEXYL) ACETIC ACID | 2011 |
|
RU2612556C2 |
| CRYSTALLINE FGFR4 INHIBITOR AND ITS APPLICATION | 2016 |
|
RU2763328C2 |
| POLYMORPHOUS AND AMORPHOUS FORMS OF {2-FLUORINE-5-[3-((E)-2-PYRIDINE-2-ILVINYL)-1N-INDAZOLE-6-ILAMINE]PHENYL}AMIDE 2, 5-DIMETHYL-2N-PYRAZOLE-3-CARBONIC ACID | 2005 |
|
RU2324692C1 |
| C-MET/HGFR INHIBITOR POLYMORPHS | 2006 |
|
RU2387650C2 |
| ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF PAH | 2020 |
|
RU2786588C1 |
| ABT-263 CRYSTALLINE FORMS AND SOLVATES FOR TREATMENT OF BCL-2 PROTEIN RELATED DISEASES | 2010 |
|
RU2551376C2 |
| SALTS AND CRYSTALLINE FORMS OF APOTTOSIS-INDUCING AGENT | 2011 |
|
RU2628560C2 |
| (1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-d]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE HYDROCHLORIDE | 2010 |
|
RU2562245C2 |
| METHOD OF PRODUCING N-[5-(3,5-DIFTORBENZIL)-1H-INDAZOLE-3-YL]-4-(4-METHYLPIPERAZINE-1-YL)-2-(TETRAHYDROPYRAN-4-YLAMINO)BENZAMIDE | 2013 |
|
RU2602071C2 |
